including translocation of Drp-1 from the cytosol to the mitochondria. We evidenced the participation of autophagy as a cytoprotective response against the toxic effects induced by this inhibitor.

Inhibitors of ... apoptosis in an MCL-1-dependent cell line. Furthermore, we observe rapid and extensive mitochondrial fission following A-1210477 that occurs in a DRP-1-dependent manner.

Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta ... Product Profiles Figure 1: The authors drug assessment summary ...

p110(delta) selective PI3 kinase inhibitor CAL-101 has broad preclinical anti-tumor activity against a range of hematologic malignancies. Data were presented in an oral presentation and two poster ...

DON (6-Diazo-5-oxo-L-norleucine) is an irreversible inhibitor ... product DRP-104 (sirpiglenastat) is an inactive prodrug of DON designed to limit systemic DON exposure while targeting glutamine ...

This patent represents a significant step forward in securing Allarity’s market position for stenoparib and the Stenoparib DRP companion ... inhibitor of PARP1/2 and Tankyrase 1 and 2.